TICKERNERD
Menu
VIVSVIVSHealthcare · Biotechnology

VIVS Stock Forecast: VivoSim Labs, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$0.29
+0.69% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$3.9M
Ticker Nerd rank
30 / 100
Median analyst target
—
Analysts covering
—
Total return, dividends reinvested
1W
−8.8%
1M
−30.5%
YTD
−83.9%
1Y
−86.2%
From 52W high
−93.9%
From 52W low
+4.3%
$0.28
$4.78
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VIVS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores VivoSim Labs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
97
Accruals
89
Issuance
64
Growth
38
Quality
32
Revisions
25
Momentum
21
Volatility
15
Value
8

Size (97): Smaller than most of the companies we track.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VIVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VIVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Oct 25Jan 26Apr 26Jul 26VIVS

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VIVS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

VIVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

VivoSim Labs, Inc. (VIVS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.5×

Cheaper than 72% of US stocks

Price / sales
34.9×

Cheaper than 7% of US stocks

Price / book
0.2×

Cheaper than 90% of US stocks

EV / EBITDA
−0.3×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
−51.4%

Higher than 5% of US stocks

Earnings growth (YoY)
−21.6%

Higher than 19% of US stocks

Gross margin
100.0%

Higher than 99% of US stocks

Operating margin
−15327.8%

Higher than 1% of US stocks

Net margin
100.0%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−343.1%

Higher than 4% of US stocks

Return on assets
−89.5%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VIVS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VIVSVivoSim Labs, Inc.$3.9M
30
GOVXGeoVax Labs, Inc.$4.8M
29
JUNSJupiter Neurosciences, Inc.$4.8M
11
APVOAptevo Therapeutics, Inc.$4.8M
26
GLMDGalmed Pharmaceuticals Ltd.$4.5M
19
JAGXJaguar Health, Inc.$4.5M
57
MLECMoolec Science SA$5.1M
3

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own VivoSim Labs, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VIVS news & analysis

VivoSim Provides Financial and Listing Compliance Update

GlobeNewsWire · 6 Aug 2026positive

VivoSim Labs announced it received notice from Nasdaq on August 4, 2026 that it regained compliance with Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million. This followed a $5.0 million milestone payment from Eli Lilly and a $1.0 million escrow release, both tied to the prior sale of its FXR program.

Why it matters — Regaining compliance removes a near-term delisting risk for VIVS, which was addressed through newly received funds from its Eli Lilly FXR program transaction.

FAQ

Frequently asked questions about VIVS stock

How does Ticker Nerd's model rank VIVS?

As at 22 Aug 2026, VivoSim Labs, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

What is the VIVS stock forecast for 2030?

No analyst covering VivoSim Labs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VIVS are extrapolating price history, which says nothing about the business.

How has VIVS stock performed over the past year?

VivoSim Labs, Inc. returned -86.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does VivoSim Labs, Inc. do?

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company specializing in the testing of drugs and drug candidates using advanced three-dimensional (3D) human tissue models of the liver and intestine.

What is the latest news on VIVS?

The most recent item we track (GlobeNewsWire, 6 Aug 2026): "VivoSim Provides Financial and Listing Compliance Update". VivoSim Labs announced it received notice from Nasdaq on August 4, 2026 that it regained compliance with Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million. This followed a $5.0 million milestone payment from Eli Lilly and a $1.0 million escrow release, both tied to the prior sale of its FXR program.

Company

About VivoSim Labs, Inc.

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company specializing in the testing of drugs and drug candidates using advanced three-dimensional (3D) human tissue models of the liver and intestine. The company employs proprietary new approach methodologies (NAM) to provide detailed insights into liver and intestinal toxicology, aiding pharmaceutical and biotech partners in investigational toxicology, mechanism of drug action elucidation, and prediction of side effect profiles during drug development. VivoSim Labs builds functional 3D human tissues that closely mimic native tissue composition, architecture, and function, including disease states, utilizing high-throughput systems, bioprinting, and flow/stretch-capable technologies. Formerly known as Organovo Holdings, Inc., the company was renamed in April 2025 and has its headquarters in San Diego, California. VivoSim Labs plays a significant role in advancing drug safety and efficacy testing through sophisticated tissue engineering and predictive toxicology platforms, contributing to improved preclinical evaluation in the healthcare biotechnology sector.

15 employees · United States · https://vivosim.ai